Surmodics, Inc. (NASDAQ:SRDX – Free Report) – Investment analysts at Zacks Research lifted their Q2 2025 earnings per share estimates for shares of Surmodics in a research note issued to investors on Monday, November 25th. Zacks Research analyst D. Dey now expects that the company will earn ($0.08) per share for the quarter, up from their prior estimate of ($0.12). The consensus estimate for Surmodics’ current full-year earnings is $0.17 per share. Zacks Research also issued estimates for Surmodics’ Q1 2026 earnings at $0.22 EPS.
Surmodics (NASDAQ:SRDX – Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.14. The company had revenue of $33.23 million during the quarter, compared to the consensus estimate of $30.69 million. Surmodics had a negative return on equity of 3.79% and a negative net margin of 9.15%.
Get Our Latest Analysis on SRDX
Surmodics Stock Down 0.1 %
Shares of NASDAQ:SRDX opened at $39.54 on Thursday. Surmodics has a 1 year low of $25.17 and a 1 year high of $42.44. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.96 and a quick ratio of 3.22. The business’s 50-day moving average is $38.51 and its 200-day moving average is $39.58. The company has a market capitalization of $566.45 million, a price-to-earnings ratio of -48.81 and a beta of 1.20.
Insider Activity
In other Surmodics news, CFO Timothy J. Arens sold 7,009 shares of Surmodics stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $39.44, for a total transaction of $276,434.96. Following the transaction, the chief financial officer now owns 70,350 shares of the company’s stock, valued at $2,774,604. This trade represents a 9.06 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 8.90% of the company’s stock.
Institutional Investors Weigh In On Surmodics
A number of hedge funds have recently made changes to their positions in the business. Gabelli Funds LLC increased its holdings in Surmodics by 393.7% in the 2nd quarter. Gabelli Funds LLC now owns 260,200 shares of the company’s stock worth $10,939,000 after acquiring an additional 207,500 shares during the last quarter. Gardner Lewis Asset Management L P bought a new stake in shares of Surmodics in the second quarter valued at approximately $8,531,000. Phocas Financial Corp. purchased a new stake in shares of Surmodics during the 3rd quarter valued at approximately $3,430,000. Nisa Investment Advisors LLC boosted its holdings in Surmodics by 4,722.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 68,429 shares of the company’s stock worth $2,877,000 after buying an additional 67,010 shares during the period. Finally, Versor Investments LP purchased a new position in Surmodics in the 2nd quarter valued at approximately $2,723,000. 96.63% of the stock is currently owned by institutional investors.
About Surmodics
Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).
See Also
- Five stocks we like better than Surmodics
- With Risk Tolerance, One Size Does Not Fit All
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- Manufacturing Stocks Investing
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Receive News & Ratings for Surmodics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics and related companies with MarketBeat.com's FREE daily email newsletter.